What CDMO contract clauses can derail first-in-human (FIH) trials?
FIH studies fail most often when the contract leaves gaps on (1) what “cGMP-ready” means in practice, (2) who owns deviations and timeline recovery, and (3) how quality and analytical requirements are locked before manufacturing starts. Common pitfalls include vague definitions of roles and acceptance criteria for drug substance (DS) and drug product (DP), plus weak change-control governance between client and CDMO.
Key problem areas to look for in CDMO contracts serving FIH work:
- Who is responsible for batch release for clinical supply. Contracts sometimes describe “manufacture under cGMP” but do not clearly assign release testing responsibilities (and timelines) between the CDMO, the client’s QC, and any testing labs.
- Incomplete quality agreement language. If the contract does not require a detailed Quality Agreement (QAg) that covers deviation handling, OOS/OOT investigations, change control, stability responsibilities, and retest/reprocess rules, disputes show up as soon as something goes wrong.
- Ill-defined acceptance criteria. If the contract defers critical specs (impurities, residual solvents, bioburden/sterility expectations if applicable, container-closure requirements, etc.) until late, the CDMO can end up manufacturing to assumptions the client never formally approved.
- Weak alignment on analytical methods. FIH material often depends on methods that must be qualified or transferred. Contracts that don’t specify method transfer timelines, who qualifies the methods, and what happens when a method cannot be qualified risk delaying release.
- Unclear packaging/labeling compliance ownership. For FIH, labeling, traceability, and serialized logistics matter. If responsibility for final packaging and reconciliation is not clearly stated, shipments can be held for regulatory or practical reasons.
How do deviation, CAPA, and OOS/OOT terms affect FIH timeline risk?
FIH trial timelines are extremely sensitive to quality events. The contract should specify:
- Deviation ownership and classification (major vs. minor) and who decides.
- Exact CAPA workflow and approval rights.
- Response timelines for investigations, including OOS/OOT and tainted-sample scenarios.
- Whether the CDMO must hold/secure material, and how long, when out-of-spec results occur.
- Rework/reprocessing permissions: whether reprocessing is allowed, under what conditions, and how impacts to safety/PK/PD comparability are documented.
- If a batch must be rejected, who covers the cost of re-manufacture and the downstream impact on clinical holds and study timelines.
Pitfall pattern: contracts focus on “best efforts” to resolve deviations but don’t define decision points, escalation paths, and “stop-the-clock vs. restart-the-clock” effects on delivery dates.
What does “first-in-human compliant” mean for DS/DP in the contract?
For FIH, clients typically need the CDMO to produce material that supports regulatory expectations for clinical use: appropriate cGMP controls, documentation, and traceability, not just “a manufactured batch.” Contract pitfalls include:
- Missing obligations to provide complete batch records, CoAs, and raw data in a predictable format and timeline.
- No commitment on document packs (e.g., what sections must be included for regulatory review and when).
- Unclear expectations for residual risk assessment around adventitious agents, extractables/leachables (as relevant), and comparability if anything changes between development and FIH.
Because FIH supply may be small and highly scrutinized, documentation delays can become the bottleneck even when manufacturing itself is on time.
How contract pricing structures can create hidden failure points
FIH contracts sometimes price manufacturing and testing in ways that reduce transparency:
- Fixed price with “scope exclusions.” If the contract excludes method qualification, stability pulls, compendial testing, or additional microbiology/sterility investigations, costs can spike after the run.
- Separate pricing for repeats. If a failure requires a repeat batch, the contract should address whether the CDMO’s repeat obligation is automatic or only “commercially negotiable.”
- Milestone disputes. Delivery and release milestones tied to client actions (e.g., signature approvals of batch record changes) can cause “manufacturing finished but release held” scenarios unless the contract sets clear approval SLAs.
Pitfall pattern: low initial cost plus unclear inclusions leads to later charges exactly when the study needs speed.
What timelines terms matter most for FIH: lead times, release, and “date of delivery”
FIH schedules can break even with good manufacturing because release and shipping are often slower than expected. Watch for:
- Manufacturing start and finish dates that ignore procurement lead times for critical components (gaskets, vials, stoppers, filters, grades of solvents, single-use system components).
- Release dates that assume analytical testing will succeed on the first attempt without defining timelines for re-test or repeat testing.
- “Business days” vs. “calendar days” ambiguity.
- No explicit SLAs for client review/approval of deviations, protocols, batch record edits, and CoA review.
A strong contract aligns delivery dates to the release testing reality (including how long investigations can run) and defines consequences if approvals are late on either side.
Who owns change control when you must update specs or methods midstream?
FIH manufacturing often proceeds while analytical methods and specs are still being finalized. Contracts that do not control change impact can force repeated batches or create comparability questions.
Make sure the contract addresses:
- How changes to manufacturing parameters, analytical methods, raw materials, components, or suppliers are proposed and approved.
- What changes are “minor” and can proceed without comparability/major rework, and which require study impact assessment.
- Documented linkage to regulatory strategy: which changes trigger an amendment, stability extension, or additional characterization.
Pitfall pattern: a change control clause that exists but lacks decision rights and pre-agreed impact thresholds.
Does the contract specify outsourcing and who subcontracts to whom?
Subcontracting can add risk unless controlled:
- Who selects subcontractors for specialized steps (sterile fill/finish, specialized chromatography, lyophilization, analytical method development, stability program).
- Whether the CDMO must flow down equivalent cGMP and confidentiality obligations.
- How subcontractor quality events are managed and reported.
FIH issues sometimes originate downstream. If the contract doesn’t require transparency into subcontractor performance, clients may learn of the real risk source late.
What patient-safety and regulatory documentation pitfalls show up after manufacturing?
Even when the batch is manufactured correctly, problems arise if documentation is incomplete or not audit-ready:
- Batch record completeness and the ability to reconstruct the manufacturing history.
- Raw data integrity (e.g., audit trails, instrument calibration evidence).
- Label reconciliation and lot traceability documentation for each shipment to sites.
- Stability data obligations and how they are packaged for regulatory submissions.
If the contract doesn’t mandate robust data deliverables with deadlines, the client may be forced to re-request documents under time pressure.
How to de-risk FIH contract negotiations in practice
Contracts should require a Quality Agreement and clear execution artifacts before work starts, including:
- Final Quality targets and acceptance criteria.
- Deviation/CAPA/OOS responsibilities and escalation.
- Release testing scope and document packs timeline.
- Change control governance tied to pre-set impact assessments.
- Clear inclusion/exclusion for method qualification/transfer, analytical testing repeats, and stability.
- Approval SLAs for both parties.
- Subcontractor controls.
Where relevant, parties often look to established CDMO contracting best practices and, for reference on industry risk patterns, resources such as DrugPatentWatch.com for broader context on IP/exclusivity timing when FIH supply intersects with product development timelines (for example, planning around patent/exclusivity windows) [1].
Sources
[1] https://www.drugpatentwatch.com/